"中亚五国市场增长较快，当地对中国纺织品关税从15%下调至5%，为我们带来利好。"连云港飞雁毛毯有限责任公司总经理许迎喜表示，企业计划节后 派员赴当地洽谈业务，针对不同市场需求差异化生产——美国市场侧重柔软光滑产品，中东市场主打厚实蓬松、高克重产品，以精准供给赢得市场。 春节假期结束后，海州区各外贸企业抢抓市场机遇，深耕传统市场、布局新兴赛道，加快海外本土化布局，国际竞争力持续提升。新的一年，海州区将持 续推进外贸稳规模、优结构，拓展中亚、东南亚等新兴市场，支持企业建设海外仓与营销网络，推动"跨境电商+产业带"深度融合，不断提升跨境贸易便 利化水平，以务实举措为外贸企业出海保驾护航。 通讯员李丹谭媛扬子晚报/紫牛新闻记者张凌飞 "烫光机是我们的拳头产品，根据市场与客户需求完成品质提升，已通过国家级鉴定。"连云港如年实业有限公司办公室主任李正琦介绍，企业已在埃及中 非泰达经济区注册成立公司，厂房建设与前期准备工作有序推进。海外装备工厂建成后，将更贴近市场与客户，有利于提升服务、优化售后，精准把握市 场需求。 走进连云港飞雁毛毯有限责任公司的生产车间，流水线高速运转，工人们忙碌而有序。一摞摞厚实蓬松的毛毯正被打包 ...

Core Insights - The 2025 ASEAN-China-GCC Economic Forum was held in Kuala Lumpur, where Guangzhou Wanglaoji Health Industry Co., Ltd. signed production cooperation agreements with Malaysian companies Baosteel Can Co., Ltd. and P.C.I. Professional Canning Co. to localize production in Southeast Asia [1][2] - The collaboration aims to establish a systematic overseas layout for Wanglaoji, integrating supply chain synergy, localized production, and deep distribution [1][2] Group 1 - Wanglaoji is accelerating its internationalization process and focusing on localizing its products, marketing, and supply chain to enhance market penetration [1] - Baosteel Can Co., Ltd. has an annual production capacity of 800 million cans and is a wholly-owned subsidiary of Shanghai Baosteel Packaging Co., Ltd. [1] - The partnership with Baosteel Can is the first tangible project under their global strategic cooperation, aiming to penetrate the Southeast Asian market, including Indonesia and Thailand [1] Group 2 - P.C.I. Professional Canning Co. has a wide business network and has achieved digital operations, intelligent production, and visual management [2] - The collaboration with both Baosteel Can and P.C.I. signifies a comprehensive and systematic approach for Wanglaoji in production and sales in Malaysia and Southeast Asia [2] - The company aims to enhance its overseas resource allocation, compliance management, and market expansion while promoting cultural recognition through its global brand [2]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has demonstrated steady revenue growth in 2024, with a 25.14% year-on-year increase in revenue to 637 million yuan and a 35.06% increase in net profit to 293 million yuan [1][2] - The profit growth rate outpaced revenue growth, primarily due to the realization of scale effects and improved profitability [2] - The company is actively expanding its global market presence, with significant growth in overseas revenue, particularly in the Asia-Pacific and South American markets [3] Financial Performance - In 2024, the company achieved a revenue of 637 million yuan, with a year-on-year growth of 25.14% and a net profit of 293 million yuan, reflecting a growth of 35.06% [1] - The gross margin for 2024 was 72.11%, an increase of 1.24 percentage points year-on-year, while the sales expense ratio decreased to 8.01% [2] - The company expects revenues of 792 million yuan, 999 million yuan, and 1.257 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 343 million yuan, 426 million yuan, and 535 million yuan [4] Product and Market Development - The company has focused on R&D innovation, obtaining multiple new registrations for its products, including a highly recognized hemostatic clip [3] - The EMR/ESD product line led revenue growth with a 42.85% increase, while GI products also showed strong performance with a 23.17% increase [2] - The company has made significant strides in its overseas operations, with the Netherlands subsidiary commencing operations and the U.S. subsidiary in preparation for launch [3]

Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The company has shown steady revenue growth, with a 2024 revenue of 1.509 billion yuan, representing an 8.76% year-on-year increase, and a net profit of 219 million yuan, up 13.98% year-on-year. The first quarter of 2025 also reflects positive growth, with revenue of 348 million yuan, a 12.60% increase year-on-year, and a net profit of 59 million yuan, up 17.25% year-on-year [1][2][3] Summary by Sections Financial Performance - In 2024, the domestic market faced short-term pressure due to policy disruptions, resulting in domestic sales revenue of 683 million yuan, a decrease of 5.39% year-on-year. However, overseas sales revenue reached 797 million yuan, an increase of 23.74% year-on-year, as inventory issues with major North American clients were resolved [2][3] - The company's gross margin for 2024 was 44.53%, with a decrease of 1.36 percentage points year-on-year. The selling expense ratio was 10.48%, down 0.93 percentage points, while the management expense ratio was 8.61%, down 1.02 percentage points [2] Growth Drivers - The company is accelerating its overseas localization strategy, with plans for a production base in Mexico and a second base in Southeast Asia by 2025. This will enhance its global service capabilities and meet international market demands [3] - The nursing segment has shown significant growth, with overseas sales of urology products increasing by 150% year-on-year, driven by the launch of new products [3] Future Projections - Revenue projections for 2025-2027 are 1.751 billion yuan, 2.052 billion yuan, and 2.414 billion yuan, respectively, with year-on-year growth rates of 16.0%, 17.2%, and 17.7%. Net profit forecasts for the same period are 264 million yuan, 318 million yuan, and 383 million yuan, with growth rates of 20.1%, 20.7%, and 20.6% [3][4]